JPWO2020185722A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020185722A5 JPWO2020185722A5 JP2021553837A JP2021553837A JPWO2020185722A5 JP WO2020185722 A5 JPWO2020185722 A5 JP WO2020185722A5 JP 2021553837 A JP2021553837 A JP 2021553837A JP 2021553837 A JP2021553837 A JP 2021553837A JP WO2020185722 A5 JPWO2020185722 A5 JP WO2020185722A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cdrs
- amino acid
- domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 67
- 125000003275 alpha amino acid group Chemical group 0.000 claims 67
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 201000011510 cancer Diseases 0.000 claims 30
- 238000006467 substitution reaction Methods 0.000 claims 29
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 16
- 230000037430 deletion Effects 0.000 claims 16
- 238000012217 deletion Methods 0.000 claims 16
- 238000003780 insertion Methods 0.000 claims 16
- 230000037431 insertion Effects 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000004988 N-glycosylation Effects 0.000 claims 12
- 239000012270 PD-1 inhibitor Substances 0.000 claims 12
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 10
- 206010033128 Ovarian cancer Diseases 0.000 claims 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 10
- 206010038389 Renal cancer Diseases 0.000 claims 10
- 201000009036 biliary tract cancer Diseases 0.000 claims 10
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 10
- 201000010982 kidney cancer Diseases 0.000 claims 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 10
- 201000002528 pancreatic cancer Diseases 0.000 claims 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 206010061424 Anal cancer Diseases 0.000 claims 5
- 208000007860 Anus Neoplasms Diseases 0.000 claims 5
- 206010073360 Appendix cancer Diseases 0.000 claims 5
- 206010005003 Bladder cancer Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 5
- 206010014733 Endometrial cancer Diseases 0.000 claims 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 5
- 108010087819 Fc receptors Proteins 0.000 claims 5
- 102000009109 Fc receptors Human genes 0.000 claims 5
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 5
- 208000017604 Hodgkin disease Diseases 0.000 claims 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 5
- 206010027406 Mesothelioma Diseases 0.000 claims 5
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 5
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 5
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 5
- 206010061934 Salivary gland cancer Diseases 0.000 claims 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 5
- 206010057644 Testis cancer Diseases 0.000 claims 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 5
- 201000005188 adrenal gland cancer Diseases 0.000 claims 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 5
- 201000011165 anus cancer Diseases 0.000 claims 5
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 5
- 229960003852 atezolizumab Drugs 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 201000000220 brain stem cancer Diseases 0.000 claims 5
- 201000007455 central nervous system cancer Diseases 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 229950009791 durvalumab Drugs 0.000 claims 5
- 201000004101 esophageal cancer Diseases 0.000 claims 5
- 206010017758 gastric cancer Diseases 0.000 claims 5
- 201000010536 head and neck cancer Diseases 0.000 claims 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 5
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 5
- 201000007270 liver cancer Diseases 0.000 claims 5
- 208000014018 liver neoplasm Diseases 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 229960003301 nivolumab Drugs 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 201000008968 osteosarcoma Diseases 0.000 claims 5
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 208000029255 peripheral nervous system cancer Diseases 0.000 claims 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 5
- 201000011549 stomach cancer Diseases 0.000 claims 5
- 201000003120 testicular cancer Diseases 0.000 claims 5
- 201000002510 thyroid cancer Diseases 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims 5
- 206010046766 uterine cancer Diseases 0.000 claims 5
- 229950002916 avelumab Drugs 0.000 claims 4
- 229960005386 ipilimumab Drugs 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 210000000813 small intestine Anatomy 0.000 claims 3
- 201000002314 small intestine cancer Diseases 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229950007217 tremelimumab Drugs 0.000 claims 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817749P | 2019-03-13 | 2019-03-13 | |
| US62/817,749 | 2019-03-13 | ||
| PCT/US2020/021783 WO2020185722A2 (en) | 2019-03-13 | 2020-03-10 | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525071A JP2022525071A (ja) | 2022-05-11 |
| JP2022525071A5 JP2022525071A5 (https=) | 2023-03-24 |
| JPWO2020185722A5 true JPWO2020185722A5 (https=) | 2023-03-24 |
| JP7581225B2 JP7581225B2 (ja) | 2024-11-12 |
Family
ID=72426465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553837A Active JP7581225B2 (ja) | 2019-03-13 | 2020-03-10 | Ｃｔｌａ－４遮断剤とｐｄ－１遮断剤とを含む抗癌併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12358986B2 (https=) |
| EP (1) | EP3937979A4 (https=) |
| JP (1) | JP7581225B2 (https=) |
| KR (1) | KR20210141539A (https=) |
| CN (1) | CN113631189A (https=) |
| AU (1) | AU2020234785A1 (https=) |
| BR (1) | BR112021017892A8 (https=) |
| CA (1) | CA3132198A1 (https=) |
| MA (1) | MA55316A (https=) |
| MX (1) | MX2021010997A (https=) |
| WO (1) | WO2020185722A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121891A1 (es) | 2020-04-22 | 2022-07-20 | Merck Sharp & Dohme | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO |
| KR20230124030A (ko) * | 2020-12-23 | 2023-08-24 | 머크 샤프 앤드 돔 엘엘씨 | 자가면역 및 염증성 질환을 치료하기 위한 il-2 뮤테인 |
| WO2022161454A1 (zh) * | 2021-01-29 | 2022-08-04 | 明慧医药（杭州）有限公司 | 抗原结合蛋白及其用途 |
| CN115197325A (zh) * | 2021-04-14 | 2022-10-18 | 康方药业有限公司 | 抗体在抗肿瘤治疗中的用途 |
| WO2022222961A1 (zh) * | 2021-04-21 | 2022-10-27 | 和铂医药(上海)有限责任公司 | 结合ctla-4的抗体及其用途 |
| KR20230110141A (ko) | 2022-01-14 | 2023-07-21 | 영남대학교 산학협력단 | PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도 |
| US11932693B2 (en) * | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| WO2025042997A1 (en) * | 2023-08-21 | 2025-02-27 | Agenus Inc. | Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| WO2025240670A2 (en) * | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| EP2102241A2 (en) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| BR112012024489A2 (pt) | 2010-03-29 | 2016-05-31 | Zymeworks Inc | anticorpos com função efetora suprimida ou aumentada |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| HRP20250902T1 (hr) * | 2015-11-18 | 2025-09-26 | Bristol-Myers Squibb Company | Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela |
| US10544222B2 (en) | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| CR20180279A (es) | 2015-11-18 | 2018-08-24 | Merck Sharp & Dohme | Enlazadores de ctla4 |
| JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| MX2019004775A (es) | 2016-11-03 | 2019-08-05 | Squibb Bristol Myers Co | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos. |
| CN110505882A (zh) * | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
| SG11201910134SA (en) * | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| EP3752193A4 (en) * | 2018-02-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES |
-
2020
- 2020-03-10 EP EP20770048.5A patent/EP3937979A4/en active Pending
- 2020-03-10 CN CN202080020847.XA patent/CN113631189A/zh active Pending
- 2020-03-10 MX MX2021010997A patent/MX2021010997A/es unknown
- 2020-03-10 BR BR112021017892A patent/BR112021017892A8/pt unknown
- 2020-03-10 MA MA055316A patent/MA55316A/fr unknown
- 2020-03-10 AU AU2020234785A patent/AU2020234785A1/en active Pending
- 2020-03-10 JP JP2021553837A patent/JP7581225B2/ja active Active
- 2020-03-10 US US17/436,857 patent/US12358986B2/en active Active
- 2020-03-10 KR KR1020217032365A patent/KR20210141539A/ko not_active Ceased
- 2020-03-10 CA CA3132198A patent/CA3132198A1/en active Pending
- 2020-03-10 WO PCT/US2020/021783 patent/WO2020185722A2/en not_active Ceased
-
2025
- 2025-06-03 US US19/226,799 patent/US20250289890A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11718681B2 (en) | Anti-SIRP α antibodies | |
| US12528876B2 (en) | CD73 blocking antibodies | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| AU2019378101B2 (en) | Humanized anti-SIRPα antibodies | |
| US20250136720A1 (en) | Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| AU2020225173A1 (en) | Anti-PD-L1 antibody and use thereof | |
| JP2025186381A (ja) | Ｃｄ１３７結合分子及びその使用 | |
| JPWO2020185722A5 (https=) | ||
| RU2021129575A (ru) | Способы комбинированного лечения злокачественных новообразований, включающие средства, блокирующие ctla-4 и pd-1 | |
| CN118139884A (zh) | 人源化抗clec-1a抗体和其抗原结合片段及其模拟物 | |
| RU2812199C2 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИ-SIRPα АНТИТЕЛА | |
| TWI913718B (zh) | 抗SIRPα抗體及其製造方法 | |
| RU2024116190A (ru) | Антитело против cd73 и его применение | |
| RU2025127414A (ru) | Антитела против 5т4 и их применения | |
| JPWO2022242680A5 (https=) | ||
| RU2021127470A (ru) | Анти-pd-l1 антитело и его применение | |
| HK40052157A (en) | Anti-pd-l1 antibody and use thereof |